The medication regulates blood sugar levels, suppresses appetite, and increases feelings of satiety
The clinical benefits, including reductions to hospitalizations due to MACE continue to be observed in the second analysis
Many patients assume they are the same thing, but while GLP-1 medications are technically peptides, not all peptide therapies are designed for weight loss
GLP-1 (glucagon-like peptide-1) receptor activation slows gastric emptying, reduces appetite through central nervous system signaling, and improves insulin response
"As we exit the first quarter, our domestic business is accelerating, were expanding into new categories and countries, and more people than ever are relying on us for access to personal, data-driven care." Hims & Hers has ambitions to become the "default health and wellness provider in the U.S.," Okupe said
In November 2024, the Biden administration proposed expanding Medicare and Medicaid coverage for anti- obesity drugs, potentially extending coverage to an estimated 3.4 million Americans insured by Medicare and an additional four million by Medicaid